Effectiveness and safety of oral Chinese patent medicines as adjuvant treatment for unstable angina pectoris on the national essential drugs list of China: a protocol for a systematic review and network meta-analysis

• Published in: BMJ open 2019-09, Vol.9 (9), p.e026136-e026136
• Main Authors: Hua, Zhen, Zhai, Feng-Ting, Tian, Jinhui, Gao, Cheng-Fei, Xu, Peng, Zhang, Fan, Liu, Si-jia, Dong, Kun, Du, Xiao-Feng, Zhang, Zhe, Yang, Guanlin
• Format: Article
• Language: English
• Subjects: Adjuvants; Angina pectoris; Angina, Unstable; Bias; Cardiovascular disease; Chinese medicine; Complementary Medicine; Drug dosages; Evidence-based medicine; Meta-analysis; Network meta-analysis; Protocol; Systematic review; Traditional Chinese Medicine
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2018-026136

IntroductionAchieving efficacious and safe treatments for unstable angina pectoris (UAP) is still a challenging clinical problem. The availability of different oral Chinese patent medicines frequently poses a practical challenge to clinicians, namely, which one to choose as first-line regimen for treatment. This study aims to examine the comparative effectiveness and safety of oral Chinese patent medicines for UAP on the national essential drugs list of China.Methods and analysisWe will conduct a network meta-analysis (NMA) of all randomised controlled trials to evaluate the use of oral Chinese patent medicines as adjuvant for the treatment of UAP. We will explore eight electronic databases from their inception to June 2018 and search for grey literature. Primary outcomes include mortality and the cardiovascular events. Secondary outcomes include: (1) symptom improvement; (2) ECG improvement; (3) frequency of acute angina attack; (4) duration of angina; (5) adverse effects. Two independent authors will screen titles and abstracts, review full texts, extract data, assess the risk of bias using the Cochrane risk of bias tool and assess the quality of evidence and strength of the recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). If adequate data are available, NMA will be performed with Bayesian analysis methods.Ethics and disseminationThe NMA will help us to reduce the uncertainty of interventions and help clinicians to make optimal and more accurate therapeutic decisions for adults with UAP. Therefore, we will publish the findings of this study in a peer-reviewed journal. No ethics approval is necessary for this study based on the nature of its design.Trial registration numberCRD42018092822.